Harvard, 10x say Vizgen infringes genomics patents

Harvard College and 10x Genomics have sued Vizgen, claiming that the Massachusetts-based biotech rival infringes five patents covering molecular analysis methods.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Harvard and 10x to face anti-competitive claims over genomics patents

13 July 2023 Delaware court permits counterclaims from Vizgen and Nanostring in separate suits | Firms say patents-in-suit were covered by ‘open and non-exclusive licenses’.

Biotechnology

10x escalates genomics patents dispute at the UPC

8 June 2023 Biotech hoping for ‘pan-European injunctive relief’ | Vizgen CEO says lawsuits an ‘attempt to undermine innovation’.

Americas

Vizgen accuses Harvard and 10x of patent licence cover-up

4 May 2023 Firm says patents-in-suit were developed using $19 million of public money | Biotech also cites “new evidence” in suit with Harvard and 10x.

More features

AIPPI: Personalised medicine tests the limits in patent law

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

‘Whose trademark law is AI based on exactly?’: Key questions from Marques

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Harvard, 10x say Vizgen infringes genomics patents

More on this story

Editor's picks

Editor's picks

More features